Who are Topical Pirfenidone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pirfenidone or nintedanib, Luspatercept Injectable Product, WINREVAIR, Pirfenidone Capsules, Invossa K Inj., BAT1706.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/topical-pirfenidone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Topical Pirfenidone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Pirfenidone (Topical Pirfenidone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrotic. Area: Pulmonology.

phase 3 Antifibrotic TGF-β Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Topical Pirfenidone (Topical Pirfenidone) — Centro Dermatológico Dr. Ladislao de la Pascua. Pirfenidone is an antifibrotic agent that inhibits the production of transforming growth factor-beta (TGF-β), a key cytokine involved in fibrosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Topical Pirfenidone TARGET	Topical Pirfenidone	Centro Dermatológico Dr. Ladislao de la Pascua	phase 3	Antifibrotic	TGF-β
pirfenidone or nintedanib	pirfenidone or nintedanib	Hospices Civils de Lyon	marketed	Antifibrotic agent	Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases
Luspatercept Injectable Product	Luspatercept Injectable Product	Sun Yat-sen University	marketed	Erythroid maturation agent	Activin A; TGF-β superfamily ligands
WINREVAIR	SOTATERCEPT-CSRK	MERCK SHARP DOHME	marketed		activin A and other TGF-β superfamily ligands
Pirfenidone Capsules	Pirfenidone Capsules	Shanghai Zhongshan Hospital	marketed	Antifibrotic agent	TGF-β pathway; multiple pro-fibrotic cytokines
Invossa K Inj.	Invossa K Inj.	Kolon Life Science	phase 3	Gene therapy (cell-based)	TGF-β1 (transforming growth factor-beta 1)
BAT1706	BAT1706	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrotic class)

Beijing Continent Pharmaceutical Co, Ltd. · 1 drug in this class
Capital Medical University · 1 drug in this class
Centro Dermatológico Dr. Ladislao de la Pascua · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical Pirfenidone — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-pirfenidone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing